MXCT - MaxCyte stock plunges 22% post-market on preliminary Q3 results
2023-10-04 16:49:14 ET
More on MaxCyte
- MaxCyte: Still Bullish Despite Soft Q2 Earnings
- MaxCyte, Inc. (MXCT) Q2 2023 Earnings Call Transcript
- MaxCyte gains on licensing pact for cell therapies
- Seeking Alpha’s Quant Rating on MaxCyte
- Historical earnings data for MaxCyte
For further details see:
MaxCyte stock plunges 22% post-market on preliminary Q3 results